glp 1 agonist vs analog The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon Science Behind GLP 1 GIP
Description
Typically, GLP-1 receptor agonists are recommended for individuals with a BMI of 30 kg/m or higher, classified as obesity, or for those with a BMI of at least 27 kg/m who also have obesity-related health conditions such as hypertension, type 2 diabetes , or high cholesterol
The emerging evidence of the Parkinson pandemic
Continuous wearable data can show trends but is easily confounded by movement, stress, and measurement artifact
Methodology: HSK
doi: 10.1248/cpb.c17-00945 58 GuSLiYJiangYHuangJHWangF
GLP-1 Receptor Agonists for the Treatment of Obesity: Role as a Promising Approach
